Scientists from the Purdue Research Foundation have prepared and tested prostate-specific membrane antigen (PSMA)-targeting ligands covalently linked to the poly(ADP-ribose) polymerase (PARP) inhibitor niraparib through a releasable, reductively cleavable NADS linker.